This episode of The Motley Fool's Market Checkup drills down on the day's hottest headlines and takes a look at two favorite health care-focused dividend stocks. Market Checkup gives a full examination of the recent regulatory action around a new blood cancer drug, a European orphan drug approval, and why a Big Pharma shockingly stopped the FDA from reviewing its newest diabetes drug.
In this video, health-care analysts David Williamson and Max Macaluso discuss Why Amgen's small but increasing dividend shouldn't be overlooked. Watch and find out about how Amgen's growth potential -- with its recent cancer-focused acquisition, next-gen cholesterol fighter, and biosimilar initiative -- combine with strong cash flow generation and a low payout ratio to form a dividend stock for the long term.
Follow David on Twitter: @MotleyDavid.
